Telaprevir for Genotype 1 Hepatitis C in HIV-Coinfected Patients

In a small phase II study of telaprevir versus placebo in combination with standard HCV therapy, SVR rates were higher among telaprevir recipients, with no detrimental effects on HIV control.

Hepatitis C virus (HCV) therapy is notorious for toxicity and poor cure rates. In HIV/HCV-coinfected patients, sustained virologic response (SVR) rates with peginterferon and ribavirin (PEG-IFN/RBV) alone are abysmal, especially for genotype 1 HCV. Adding telaprevir (TVR) or boceprevir to PEG-IFN/RBV boosts SVR rates in patients monoinfected with genotype 1 HCV and is now standard of care; however, few data exist on use of this approach in HIV/HCV-coinfected patients.

In a recent industry-sponsored, phase IIa, double-blind, multinational study, investigators randomized 60 HIV-infected, HCV treatment–naive adults with genotype 1 HCV (88% men; 85% with baseline HCV RNA ≥800,000 IU/mL) to receive either TVR or placebo, each in combination with …

Reviewing Author

Brian R. Wood, MD

Telaprevir for Genotype 1 Hepatitis C in HIV-Coinfected Patients

Topics

Reviewing Author